Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
101 Leser
Artikel bewerten:
(0)

Shu-Tung Li, Founder and CEO of Collagen Matrix, Inc. Selected for Induction into the New Jersey Inventors Hall of Fame

OAKLAND, N.J., Aug. 15, 2012 /PRNewswire/ --Collagen Matrix, Inc., the leader in collagen- and mineral-based matrix engineering, announced today that Dr. Shu-Tung Li, the Company's Founder, President, and Chief Executive Officer was selected as a 2012 inductee into the New Jersey Inventors Hall of Fame co-sponsored by Stevens Institute of Technology and Greenberg Traurig, LLP. His award recognition is for: "Patented Technology Related to: Collagen based medical implants for the repair and regeneration of soft tissue and bones." The award will be presented at a black tie dinner to be held at the W Hotel, Hoboken, N.J. on Thursday, October 18, 2012.

Dr. Li has over 40 years of experience in connective tissue research and collagen-based implant development, which includes 10 years of basic science research experience at the University of Connecticut Health Center related to the structure and function of collagen fibrils in mineralized and non-mineralized tissues and 30 years of experience in collagen-based and mineral-based medical implants development in the medical device industry.

Dr. Li has 30 U.S. patents, eight U.S. patents still pending and has authored over 95 publications. He was awarded 14 grants (12 Small Business Innovative Research grants, one National Institutes of Health R01 research grant, and one New Jersey Science and Technology Award) from 1996-2002 totaling about $8 million in the areas of collagen biomaterials, science and technology for medical applications. Throughout his career, Dr. Li has developed more than 30 collagen- and mineral-based implants that are currently on the market. He was awarded the New Jersey Executive of the Year in 2009 for his accomplishment of growing Collagen Matrix, Inc. to one of the 50 Fastest Growing Companies in New Jersey hosted by NJBIZ and presented by Amper, Politziner and Mattia, Certified Public Accountants and Consultants, and a 2011 Asian American Community Leadership Award presented by the New Jersey Asian American Association for Human Services.

"I believe that innovation is the backbone of economic growth and technological advancement. I am honored by this recognition," said Dr. Li.

Prior to founding Collagen Matrix, Dr. Li was the Co-Founder, Executive Vice President of Research and Development and a Board Member at ReGen Biologics, Inc., an orthopaedic company specializing in the development of meniscus repair devices. In his career, Dr. Li has also held management positions at Colla-Tec/Integra Lifesciences and Meadox Medicals/Boston Scientific. Dr. Li received his Ph.D. in Physical Chemistry from the University of Connecticut.

About Collagen Matrix: Collagen Matrix, Inc. is a leader in the design and engineering of collagen- and mineral-based extracellular matrices for tissue and organ repair and regeneration. Since its inception in 1997, the Company has received many government grants for the development of collagen-based matrix products in the areas of neurological, vascular, urological, and orthopedic tissue regeneration applications. The Company currently manufactures collagen- and mineral-based finished medical devices in the areas of neurosurgery, oral surgery, orthopedic-spine surgery, and wound care. More information about the Company can be found at www.collagenmatrix.com.

Contact:

Peggy Hansen, RAC


Collagen Matrix, Inc.


VP, Clinical, Regulatory, Quality Assurance/Quality Control, and Marketing


201-405-1477 x304

SOURCE Collagen Matrix, Inc.

© 2012 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.